Business Standard

Tuesday, December 24, 2024 | 12:56 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

US to pay Pfizer, BioNTech $1.95 bn for 100 mn Covid-19 vaccine doses

The companies will not receive any money from the government unless their vaccine succeeds in large clinical trials

An officer from the New York Police Department helps workers carry a body out of a house amid the coronavirus disease. Photo: Reuters
Premium

An officer from the New York Police Department helps workers carry a body out of a house amid the coronavirus disease. Photo: Reuters

Michael Erman and Ankur Banerjee | Reuters
The U.S. government will pay $1.95 billion to buy 100 million doses of a Covid-19 vaccine being developed by Pfizer Inc and German biotech BioNTech SE if it proves to be safe and effective, the companies said on Wednesday.

The contract is the most the United States has agreed to spend on a vaccine, although previous deals with other vaccine makers were intended to also help pay for development costs.

Pfizer and BioNTech will not receive any money from the government unless their vaccine succeeds in large clinical trials and can be successfully manufactured, according to a Pfizer spokeswoman.

Under the agreement, the

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in